Fuck Alzheimer's

A postmortem study of brain tissue tests and interviews of those close to the deceased ties some psychiatric symptoms to early Alzheimer’s disease. Read & Research Alzheimer’s More

Reimbursement of amyloid-PET is lagging due to the lack of definitive evidence on its clinical utility and cost-effectiveness. The Amyloid Imaging to Prevent Alzheimer’s Disease–Diagnostic and Patient Management Study (AMYPAD-DPMS) is designed to fill this gap. Read & Research Alzheimer’s More

We read the recent article by Sommerlad et al. [1] with great interest. This important study showed that, for patients aged >65 years who were known to mental health services with a diagnosis of dementia and who were subsequently admitted to a general medical hospital, only 63.3% received a dementia International Classification Read & Research Alzheimer’s More

Our diets can influence the state of our health. Research in mice now suggests that one regimen — the ketogenic diet — may even prevent cognitive decline. Read & Research Alzheimer’s More

Bile acids (BAs) are the end products of cholesterol metabolism produced by human and gut microbiome co-metabolism. Recent evidence suggests gut microbiota influence pathological features of Alzheimer’s disease (AD) including neuroinflammation and amyloid-β deposition. Read & Research Alzheimer’s More

The findings of a new study suggest that some antidepressants may block the growth of toxic plaques in the brain, thus helping to treat dementia. Read & Research Alzheimer’s More

Increasing evidence suggests a role for the gut microbiome in central nervous system disorders and a specific role for the gut-brain axis in neurodegeneration. Bile acids (BAs), products of cholesterol metabolism and clearance, are produced in the liver and are further metabolized by gut bacteria. They have major regulatory and Read & Research Alzheimer’s More

The overall goal of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) is to validate biomarkers for Alzheimer’s disease (AD) clinical trials. ADNI is a multisite, longitudinal, observational study that has collected many biomarkers since 2004. Recent publications highlight the multifactorial nature of late-onset AD. We discuss selected topics that provide insights Read & Research Alzheimer’s More

Altered cell cycle reentry has been observed in Alzheimer’s disease (AD). DTL was predicted as the top driver of a cell cycle subnetwork associated with AD. Read & Research Alzheimer’s More

We tested the hypotheses that higher levels of and persistence of midlife leisure-time physical activity (LTPA) for a long term are associated with lower cognitive decline and less incident dementia. Read & Research Alzheimer’s More

Hearing and sight loss are tied to faster cognitive decline, so does addressing these issues slow down cognitive deterioration? New studies investigate. Read & Research Alzheimer’s More

People with atrial fibrillation (irregular heartbeat) face an increased risk of dementia, a new study warns; but common drugs may keep that risk in check. Read & Research Alzheimer’s More

The Alzheimer’s Association convened a multidisciplinary workgroup to develop appropriate use criteria to guide the safe and optimal use of the lumbar puncture procedure and cerebrospinal fluid (CSF) testing for Alzheimer’s disease pathology detection in the diagnostic process. Read & Research Alzheimer’s More

We explore here a novel model for amyloidogenesis in Alzheimer’s disease (AD). This new perspective on AD amyloidosis seeks to provide a rational framework for incorporating recent and seemingly independent findings on the antimicrobial role of β-amyloid and emerging experimental, genetic, and epidemiological data, suggesting innate immune-mediated inflammation propagates AD Read & Research Alzheimer’s More

Dementia is an umbrella term that describes symptoms affecting memory and cognitive function. Alzheimer’s disease is a specific, and the most common, type of dementia. The conditions overlap in terms of symptoms, but Alzheimer’s has different and specific treatments as well as unique symptoms. Learn more here. Read & Research Alzheimer’s More

Predicting who will develop dementia is difficult. Researchers are testing various biomarkers, but a recent study asks whether apathy might provide a clue. Read & Research Alzheimer’s More

Neurodegenerative diseases encompass a range of diagnoses, such as Alzheimer’s disease and Parkinson’s disease. Despite decades of advancements in understanding the neurobiology of individual diseases, this class has few disease-modifying therapeutics and a paucity of biomarkers for diagnosis or progression. However, tau protein aggregation has emerged as a potential unifying Read & Research Alzheimer’s More

Little is known about factors affecting motivation and satisfaction of participants in dementia prevention trials. Read & Research Alzheimer’s More

At an estimated $277 billion in 2018 dollars, Alzheimer’s disease (AD) is the most expensive disease in the United States. By 2050, the cost could be as high as $1.1 trillion. AD is the sixth leading cause of death in the United States. AD-related deaths from 2000 to 2015 increased Read & Research Alzheimer’s More

Read & Research Alzheimer’s More

New research supports the idea that physical activity delays cognitive decline and other changes in the rare early-onset form of Alzheimer’s disease. Read & Research Alzheimer’s More

Now that scientists agree that oligomer protein deposits cause Alzheimer’s, an international team has detailed a plan for developing drugs to target them. Read & Research Alzheimer’s More

The first study to ever predict Alzheimer’s prevalence by race and ethnicity estimates that the United States burden of the disease will double by 2060. Read & Research Alzheimer’s More

Little is known about effects of physical activity (PA) in genetically driven early-onset autosomal dominant Alzheimer’s disease (AD). Read & Research Alzheimer’s More

A number of risk factors are known for dementia; these include hypertension, a sedentary lifestyle, obesity, and smoking. A new study may add another. Read & Research Alzheimer’s More

We tested the hypothesis that low plasma complement C3 is observationally and genetically associated with high risk of Alzheimer’s disease. Read & Research Alzheimer’s More

We sought to examine the genetic overlap between vascular pathologies and Alzheimer’s disease (AD) dementia, and the potential mediating role of vascular pathologies between AD-related genetic variants and late-life cognition. Read & Research Alzheimer’s More

In 2016, the UC Davis Latino Aging Research Resource Center and UC Davis Alzheimer’s Disease Center brought together experts from across the country to consolidate current knowledge and identify future directions in aging and diversity research. This report disseminates the research priorities that emerged from this conference, building on an Read & Research Alzheimer’s More

The objective of this study was to examine the prevalence of the coexistence of parkinsonism in patients with mild cognitive impairment (MCI) or mild Alzheimer’s disease (AD). Read & Research Alzheimer’s More

Several concepts, which in the aggregate get might be used to account for “resilience” against age- and disease-related changes, have been the subject of much research. These include brain reserve, cognitive reserve, and brain maintenance. However, different investigators have use these terms in different ways, and there has never been Read & Research Alzheimer’s More